^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | CTX-009 (VEGF-A inhibitor, DLL4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Published date:
04/25/2024
Excerpt:
Compass Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for the treatment of patients with metastatic or locally advanced BTC that have been previously treated.
Secondary therapy:
paclitaxel
